Zusammenfassung
Kutane T-Zell-Lymphome stellen extranodale Non-Hodgkin-Lymphome reifer T-Lymphozyten
dar, die die Haut als Zielorgan haben, dort zu Beginn verbleiben und proliferieren.
Sie zeigen eine große Bandbreite klinischer und histologischer Erscheinungsformen
und Merkmale. Im Gegensatz zu den nodalen Lymphomen sind ca. 80 % der kutanen Lymphome
T-Zell-Lymphome (CTCL, engl. cutaneous T cell lymphoma) und ca. 10 – 20 % B-Zell-Lymphome
(CBCL, engl. cutaneous B cell lymphoma). Der Rest entspricht seltenen Entitäten wie
die CD4+/CD56+-hämatodermischen Lymphome, deren Ursprungszelle Typ 2 dendritischen
Zellen entsprechen. Aufgrund der Heterogenität der kutanen Lymphome und ihrer unterschiedlichen
biologischen Potenz, die von einem benigne-indolenten bis hin zu einem fatalen Verlauf
reicht, ist eine genaue Typisierung des Tumors für das weitere Vorrgehen unabdingbar.
Insbesondere die Dermatohistologie, in Kombination mit der Immunhistologie und der
Molekularbiologie, spielen eine entscheidende Rolle um die richtige Therapiewahl zu
treffen.
Abstract
Cutaneous T-cell lymphomas represent extranodal non-Hodgkin lymphomas consisting of
mature lymphocytic populations targeting the skin, persisting and proliferating initially
in the skin environment. Cutaneous lymphomas reveal a broad variety of clinical manifestations
and histological pictures. In contrast to lymphomas of nodal origin, 80 % of all cutaneous
lymphomas (CTCL) derive from T-cell populations, the other 10 – 20 % being of B-cell
origin (CBCL). The remaining number of lymphomas correspond to rare entities, such
as CD4+/CD56+ hematodermic lymphomas, deriving from type-2 dendritic cells. Based
on the heterogeneity of these tumours and their varying biological potency, showing
long-term benign or fatal clinical courses, there is a strong need for clarifying
the type of the tumour, including its cell of origin. Classical histological examination
together with immunochemistry and molecular biological techniques are the most important
factors for introducing proper treatment.
Literatur
- 1
Assaf C, Hummel M, Steinhoff M. et al .
TCR-beta and TCR-gamma PCR detection of T-cell clonality indicates minimal tumor disease
in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications.
Blood.
2005;
105
503-510
- 2
Assaf C.
The clinical impact of T cell receptor rearrangement analysis in cutaneous T cell
lymphoma.
Front Radiat Ther Oncol.
2006;
39
16-24
- 3
Assaf C, Hirsch B, Wagner F. et al .
Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive
lymphoproliferations.
J Invest Dermatol.
2007;
127
1898-1904
- 4
Assaf C, Gellrich S, Whittaker S. et al .
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous
Lymphoma Project Group of the European Organisation for Research and Treatment of
Cancer.
J Clin Pathol.
2007;
60
981-989
- 5
Balfour E M, Glusac E J, Heald P. et al .
Sezary syndrome: cutaneous immunoperoxidase double-labeling technique demonstrates
CD4/CD8 ratio non-specificity.
J Cutan Pathol.
2003;
30
437-442
- 6
Bekkenk M W, Jansen P M, Meijer C J. et al .
CD56+ haematological neoplasms presenting in the skin: a retrospective analysis of
23 new cases and 130 cases from the literature.
Ann Oncol.
2004;
15
1097-1108
- 7
Cerroni L, Volkenandt M, Rieger E. et al .
Bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation
in cutaneous lymphomas and pseudolymphomas.
J Invest Dermatol.
1994;
102
231-235
- 8
Chan J K, Sin V C, Wong K F. et al .
Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic
study of 49 cases of an uncommon aggressive neoplasm.
Blood.
1997;
89
4501-4513
- 9
Child F J. et al .
Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma.
Br J Dermatol.
2001;
144
735-744
- 10
Glusac E J.
Criterion by criterion, mycosis fungoides.
Am J Dermatopathol.
2003;
25
264-269
- 11
Hoefnagel J J. et al .
Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for
a follicle centre cell origin and differential diagnostic significance.
Br J Dermatol.
2003;
149
1183-1191
- 12
Kadin M. et al .
Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing
Hodgkin's disease-associated antigens.
Am J Pathol.
1985;
119
315-325
- 13
Kamarashev J. et al .
Comparative analysis of histological and immunohistological features in mycosis fungoides
and Sezary syndrome.
J Cutan Pathol.
1998;
25
407-412
- 14
Kempf W, Ostheeren-Michaelis S, Paulli M. et al .
Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study
of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization
For Research and Treatment of Cancer (EORTC).
Arch Dermatol.
2008;
144
1609-1617
- 15
Klemke C D, Dippel E, Dembinski A. et al .
Clonal T cell receptor gamma-chain gene rearrangement by PCR-based GeneScan analysis
in the skin and blood of patients with parapsoriasis and early-stage mycosis fungoides.
J Pathol.
2002;
197
348-354
- 16
Kodama K, Massone C, Chott A. et al .
Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification,
and prognostic factors in a large series of patients.
Blood.
2005;
106
2491-2497
- 17
Massone C, Kodama K, Kerl H. et al .
Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic
study on 745 biopsy specimens from 427 patients.
Am J Surg Pathol.
2005;
29
550-560
- 18
Willemze R, Janssen P M, Cerroni L. et al .
Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic
factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases.
Blood.
2008;
111
838-845
- 19
Mirza I, Macpherson N, Paproski S. et al .
Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic,
immunophenotypic, and molecular features.
J Clin Oncol.
2002;
20
647-655
- 20
Nakamura S, Suchi T, Koshikawa T. et al .
Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in
sites other than the upper and lower respiratory tract.
Am J Surg Pathol.
1995;
19
284-296
- 21
Petrella T, Comeau M R, Maynadié M. et al .
“Agranular CD4+ CD56+ hematodermic neoplasm” (blastic NK-cell lymphoma) originates
from a population of CD56+ precursor cells related to plasmacytoid monocytes.
Am J Surg Pathol.
2002;
26
852-862
- 22
Poszepczynska-Guigne E, Schiavon V, D'Incan M. et al .
CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis
and follow-up of Sezary syndrome.
J Invest Dermatol.
2004;
122
820-823
- 23
Sandberg Y, Heule F, Lam K. et al .
Molecular immunoglobulin/T- cell receptor clonality analysis in cutaneous lymphoproliferations.
Experience with the BIOMED-2 standardized polymerase chain reaction protocol.
Haematologica.
2003;
88
659-670
- 24
Schreuder M I. et al .
FISH analysis of MALT lymphoma-specific translocations and aneuploidy in primary cutaneous
marginal zone lymphoma.
J Pathol.
2005;
205
302-310
- 25
Stadler R, Assaf C, Klemke C D. et al .
Short German guidelines: Cutaneous lymphomas.
J Dtsch Dermatol Ges.
2008;
6 Suppl 1
S25-S31
- 26
Stein H, Mason D Y, Gerdes J. et al .
The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic
lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are
derived from activated lymphoid cells.
Blood.
1985;
66
848-858
- 27
Streubel B, Lamprecht A, Dierlamm J. et al .
T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in
MALT lymphoma.
Blood.
2003;
101
2335-2339
- 28
Streubel B, Vinatzer U, Lamprecht A. et al .
T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration
in MALT lymphoma.
Leukemia.
2005;
19
652-658
- 29
Willemze R, Meyer C J, Van Vloten W A. et al .
The clinical and histological spectrum of lymphomatoid papulosis.
Br J Dermatol.
1982;
107
131-144
- 30
Willemze R, Jaffe E S, Burg G. et al .
WHO-EORTC classification for cutaneous lymphomas.
Blood.
2005;
105
3768-3785
1 Diese Arbeit ist dem 10-jährigen Jubiläum der Berliner Stiftung für Dermatologie
(BSD) und der bisher geleisteten Unterstützung an vielen jüngeren Kollegen in ihrer
Weiterbildung und Forschung gewidmet.
Priv.-Doz. Dr. Chalid Assaf
Chefarzt der Klinik für Dermatologie, Venerologie und Allergologie
HELIOS Klinikum Krefeld
Lutherplatz 40
47805 Krefeld
Email: chalid.assaf@helios-kliniken.de